Research Progress of Computer-aided Drug Sensitivity Prediction for Non-small Cell Lung Cancer with EGFR Mutation

Epidermal growth factor receptor(EGFR) is not only a common driver gene of non-small cell lung cancer (NSCLC), but also an important therapeutic target for NSCLC in clinical practice. However, the drug resistance problem caused by EGFR mutation seriously affects the therapeutic effect of targeted drugs and limits the development of precision medicine. In this paper, the target binding mode of the currently marketed EGFR tyrosine kinase inhibitors(EGFR-TKIs) is described to provide a theoretical basis for the development of novel EGFR-TKIs. And the research progress of applying computer to predict the drug sensitivity of EGFR mutants is reviewed, with the aim of promoting the development of auxiliary clinical decision-making tools for personalized treatment planning.